Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Journey Medical Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
44.5
63.1
73.7
79.2
56.1
61.9
Cost of revenue
14.6
32.1
30.8
22.9
20.9
20.9
Gross profit
29.9
31.1
42.9
56.3
35.3
40.9
Research and development
2.74
10.9
7.54
9.86
0.48
Selling, general and administrative
22.1
39.8
59.5
43.9
40.2
44.4
Operating income
7.85
-34.9
-27.5
-2.07
-13.7
-8.17
Interest expense
0.7
7.03
2.02
1.7
2.7
3.7
Other non-operating income
-0.7
-7.48
-2.05
-1.56
-0.93
-3.2
Pre-tax income
7.15
-42.4
-29.6
-3.63
-14.6
-11.4
Income tax
1.87
1.63
0.06
0.22
0.06
0.06
Net income
5.28
-44
-29.6
-3.85
-14.7
-11.4
EBITDA
7.86
-34.9
EPS, basic
0.58
-4.32
-1.69
-0.21
-0.72
-0.47
EPS, diluted
0.49
-4.32
-1.69
-0.21
-0.72
-0.47
Shares, basic (weighted)
9.14
10.2
17.5
18.2
20.4
24.5
Shares, diluted (weighted)
10.8
10.2
17.5
18.2
20.4
24.5
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
8.25
49.1
32
27.4
20.3
24.1
Receivables
23.9
23.1
28.2
15.2
10.2
29.8
Inventory
1.4
9.86
14.2
10.2
14.4
9.62
Other current assets
1.66
2.44
3.31
3.59
3.21
3.38
Total current assets
35.2
84.5
77.7
56.5
48.2
66.9
Lease right-of-use assets
0.18
0.09
0.19
0.1
0.2
0.11
Intangible assets
15
12.6
27.2
20.3
31.9
27.6
Other non-current assets
0.01
0.15
0.1
0.01
Total assets
51.9
97.3
105
76.8
80.2
94.6
Accounts payable
1.84
22.8
36.6
18.1
16.1
8.85
Accrued liabilities
21.5
22.7
19.4
20.4
17.4
27.6
Total current liabilities
28.1
51.6
66.8
41.9
35.2
37.4
Long-term debt
19.8
14.6
24.9
25.3
Lease liabilities
0.1
0.11
0.01
0.12
0.02
Total liabilities
41.6
55.2
88.2
56.5
60.2
62.7
Total debt
27.8
14.6
24.9
25.3
Paid-in capital
5.17
80.9
85.5
92.7
107
130
Retained earnings
5.12
-38.9
-68.5
-72.4
-87
-98.5
Shareholders' equity
10.3
42
17
20.4
20.1
31.9
Total equity
10.3
42
17
20.4
20.1
31.9
Total liabilities and equity
51.9
97.3
105
76.8
80.2
94.6
Shares outstanding
3.15
11.3
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
5.28
-44
-29.6
-3.85
-14.7
-11.4
Depreciation and amortization
0.01
0
Stock-based compensation
0.15
2.47
4.43
2.61
6.1
6.29
Deferred income tax
-0.34
1.57
Change in receivables
-5.02
0.77
-5.38
12.6
4.48
-19.3
Change in inventory
-0.55
-8.46
1.74
3.95
-4.23
4.81
Change in payables
-0.2
20.4
14.3
-18.4
-2.1
-7.2
Cash from operations
5.13
-2.18
-13.5
5.24
-9.13
-12.4
Capital expenditures
-20
-5
-15
Cash from investing
-1.2
-10
-20
-5
-15
Stock issued
0.01
32.5
0.14
4.49
7.88
16.4
Cash from financing
-0.49
53
16.5
-4.8
17
16.2
Net change in cash
3.45
40.8
-17.1
-4.56
-7.13
3.79
Free cash flow
-33.5
0.24
-24.1
Interest paid
0.99
1.13
2.01
3.24
Income taxes paid
0.11
0.16
0.17
0.18
0.13
0.05
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.14 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-4.4%
Operating income / revenue.
Pre-tax margin
-8.9%
Pre-tax income / revenue.
Net margin
-9.0%
Net income / revenue.
Operating cash flow margin
-11.0%
Cash from operations / revenue.
Return on equity (ROE)
-19.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-6.2%
Net income / average total assets.
Return on invested capital (ROIC)
-7.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
SG&A / revenue
62.9%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
8.9%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
10.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-5.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
6.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
16.1%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-1.5%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
6.5%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
58.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
23.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
25.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
17.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-3.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
12.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
19.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
11.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
17.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.59x
Current assets / current liabilities.
Quick ratio
1.35x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.56x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.79x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
25.9%
Total debt / total assets.
Liabilities / assets
67.3%
Total liabilities / total assets.
Net debt
-$171.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.48
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.27
Cash from operations / diluted weighted shares.
Book value per share
$1.17
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.54x
Market cap / revenue.
P/B
5.40x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
26.2x
Market cap / tangible book value, when positive.
EV/Sales
2.54x
Enterprise value / revenue.
Earnings yield
-3.5%
Net income / market cap (the inverse of P/E).
What was Journey Medical Corp's revenue in fiscal 2025?
Journey Medical Corp reported revenue of $61.9M for fiscal 2025, 10.2% higher than the year before.
Was Journey Medical Corp profitable in fiscal 2025?
No. It reported a net loss of $11.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.